Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

Diabetes Care

Volumn 32, Issue 11, 2009, Pages 2068-2074

  Zoungas, Sophia ^a,b   De Galan, Bastiaan E ^a,c   Ninomiya, Toshiharu ^a   Grobbee, Diederick ^d   Hamet, Pavel ^e   Heller, Simon ^f   MacMahon, Stephen ^a   Marre, Michel ^g   Neal, Bruce ^a   Patel, Anushka ^a   Woodward, Mark ^a,h   Chalmers, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g BICHAT HOSPITAL   (France)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO; SULFONYLUREA DERIVATIVE;

AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROPHYLAXIS; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLICLAZIDE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INDAPAMIDE; MALE; MICROCIRCULATION; MIDDLE AGED; PERINDOPRIL; PLACEBOS;

EID: 70449360911     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0959     Document Type: Article

References (22)

1. International Diabetes Federation. Diabetes Atlas. 3rd ed. Brussels, International Diabetes Federation, 2006
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
3. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355: 253-259
4. Patel A, MacMahon S, Chalmers J, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840
5. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
6. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetes patients. Diabetes Care 2000;23(Suppl. 2):B21-B29 (Pubitemid 30185774)
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS33).Lancet1998;352: 837-853
8. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
9. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2543-2553
10. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
11. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Perdersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
12. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(Suppl. 1):S12-S54
13. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels, International Diabetes Federation, 2005
14. Stratton IM, Matthews DR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006;49:1761-1769
15. ADVANCE Management Committee. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular Disease: Preterax and Diamicron MR controlled evaluation. Diabetologia 2001;44:1118-1120
16. Woodward M. epidemiology: study design and data analysis. 2nd ed. Boca Raton, FL, Chapman and Hall/CRC Press, 2005
17. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008;5:e207
18. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE Brenner BM. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-927 (Pubitemid 39128617)
19. Holman RR, Paul SK, Bethel MA, Matthews DR, and Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
20. Piantadosi S. Clinical Trials: a Methodologic Perspective. 2nd ed. Hoboken, NJ, John Wiley & Sons, 2005
21. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444 (Pubitemid 23046633)
22. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow up. Diabetologia 1996;39:1577-1583 (Pubitemid 26397370)